Form 8-K

8-K — ALTRIA GROUP, INC.

Accession: 0000764180-26-000056

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000764180

SIC: 2111 (CIGARETTES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — mo-20260430.htm (Primary)

EX-99.1 — ALTRIA GROUP, INC. EARNINGS PRESS RELEASE, DATED APRIL 30, 2026 (exhibit991erq12026.htm)

GRAPHIC (altriamosaica62a.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: mo-20260430.htm · Sequence: 1

mo-20260430

false000076418000007641802026-04-302026-04-300000764180mo:CommonStock0.3313ParValueMember2026-04-302026-04-300000764180mo:CommonStock2.200NotesDue2027Member2026-04-302026-04-300000764180mo:CommonStock3.125NotesDue2031Member2026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________________________________________________________

FORM 8-K

________________________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2026

________________________________________________________________________________________________________________

ALTRIA GROUP, INC.

(Exact name of registrant as specified in its charter)

______________________________________________________________________________________________________________

Virginia 1-08940 13-3260245

(State or other jurisdiction

of incorporation) (Commission File Number) (I.R.S. Employer

Identification No.)

6601 West Broad Street, Richmond, Virginia 23230

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (804) 274-2200

_______________________________________________________________________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols Name of each exchange on which registered

Common Stock, $0.33 1/3 par value

MO New York Stock Exchange

2.200% Notes due 2027

MO27 New York Stock Exchange

3.125% Notes due 2031

MO31 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On April 30, 2026, Altria Group, Inc. (“Altria”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference in this Item 2.02.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1

Altria Group, Inc. Press Release, dated April 30, 2026 (furnished under Item 2.02)

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALTRIA GROUP, INC.

By: /s/ MARY C. BIGELOW

Name: Mary C. Bigelow

Title: Vice President, Corporate Secretary and

Associate General Counsel

DATE: April 30, 2026

EX-99.1 — ALTRIA GROUP, INC. EARNINGS PRESS RELEASE, DATED APRIL 30, 2026

EX-99.1

Filename: exhibit991erq12026.htm · Sequence: 2

Document

Exhibit 99.1

Altria Reports 2026 First-Quarter Results;

Reaffirms Full-Year Guidance

RICHMOND, Va. - April 30, 2026 - Altria Group, Inc. (NYSE: MO) today reports our 2026 first-quarter business results and reaffirms our guidance for 2026 full-year adjusted diluted earnings per share (EPS).

“We delivered a strong start to the year, growing adjusted diluted EPS by 7.3% in the first quarter,” said Billy Gifford, Altria’s Chief Executive Officer. “Our highly cash-generative businesses supported significant returns to shareholders through dividends and share repurchases, while we continued to invest in support of our Vision.”

“Our smokeable products segment generated strong income growth. Marlboro strengthened its position in the premium segment, and PM USA continued to execute its total portfolio strategy with discipline. In the oral tobacco products segment, on! performed well in a highly competitive marketplace and Helix expanded on! PLUS nationwide.”

“We reaffirm our expectation to deliver 2026 full-year adjusted diluted EPS in a range of $5.56 to $5.72, representing a growth rate of 2.5% to 5.5% from a base of $5.42 in 2025.”

Altria Headline Financials 1

($ in millions, except per share data) Q1 2026 Change vs.

Q1 2025

Net revenues $5,428 3.2%

Revenues net of excise taxes $4,758 5.3%

Reported effective tax rate 23.6% (12.4) pp

Adjusted effective tax rate 23.1% (0.4) pp

Reported diluted EPS $1.30 100%+

Adjusted diluted EPS $1.32 7.3%

1 “Adjusted” financial measures presented in this release exclude the impact of special items. See “Basis of Presentation” for more information and see the schedules to this press release for reconciliations to corresponding GAAP measures.

As previously announced, a conference call with the investment community and news media will be webcast on April 30, 2026 at 9:00 a.m. Eastern Time. Access to the webcast is available at www.altria.com/webcasts.

6601 West Broad Street, Richmond VA 23230

Cash Returns to Shareholders

Share Repurchase Program

•In the first quarter of 2026, we repurchased 4.5 million shares at an average price of $62.33 per share, for a total cost of $280 million.

•As of March 31, 2026, we had $720 million remaining under our $2 billion share repurchase program, which expires on December 31, 2026. Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board of Directors (Board).

Dividends

•We paid dividends of $1.8 billion in the first quarter. Future dividend payments remain subject to the discretion of our Board.

2026 Full-Year Guidance

We reaffirm our guidance to deliver 2026 full-year adjusted diluted EPS in a range of $5.56 to $5.72, representing a growth rate of 2.5% to 5.5% from a base of $5.42 in 2025. As a result of the strong first-quarter performance, we now expect 2026 adjusted diluted EPS growth to be more balanced between the first half and the second half of the year.

Our reaffirmed guidance range now contemplates the impact of moderated e-vapor industry growth on combustible and e-vapor product volumes and increased macroeconomic uncertainty facing adult nicotine consumers.

As previously disclosed, our guidance also contemplates:

(i) a progressive increase in cigarette import and export activity over the course of the year;

(ii) planned investments in support of our contract manufacturing capabilities;

(iii) that NJOY ACE does not return to the marketplace in 2026;

(iv) reinvestment of anticipated cost savings related to our Optimize & Accelerate initiative (Initiative); and

(v) planned investments in support of our Vision.

Our full-year adjusted diluted EPS guidance range excludes the impact of certain income and expense items that our management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition, disposition and integration-related items, equity investment-related special items, certain income tax items, charges associated with tobacco and health and certain other litigation items, resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the Master Settlement Agreement (NPM Adjustment Items) and amortization expense associated with definite-lived intangible assets (amortization of intangibles). See Table 1 below for the income and expense items for the first quarter of 2026.

Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding GAAP measure for, or reconciliation to, our adjusted diluted EPS guidance.

ALTRIA GROUP, INC.

See “Basis of Presentation” for an explanation of the financial measures and reportable segments discussed in this release.

Financial Performance

•Net revenues increased 3.2% to $5.4 billion, primarily driven by higher net revenues in the smokeable products segment. Revenues net of excise taxes increased 5.3% to $4.8 billion.

•Reported diluted EPS increased over 100% to $1.30, primarily driven by higher reported operating companies income (OCI), which includes the 2025 non-cash impairment of the e-vapor reporting unit goodwill and lower costs associated with the acquisition of NJOY.

•Adjusted diluted EPS increased 7.3% to $1.32, driven by higher adjusted OCI and fewer shares outstanding.

Table 1 - Altria’s Adjusted Results

First Quarter

2026 2025 Change

Reported diluted EPS $ 1.30 $ 0.63 100%+

Acquisition-related items — 0.04

Asset impairment, exit and implementation costs — 0.52

Tobacco and health and certain other litigation items — 0.02

Amortization of intangibles 0.01 0.02

ABI-related special items — 0.01

Cronos-related special items — (0.01)

Income tax items 0.01 —

Adjusted diluted EPS $ 1.32 $ 1.23 7.3 %

Note: For details of pre-tax, tax and after-tax amounts, see Schedule 5.

Special Items

The EPS impact of the following special items is shown in Table 1 and Schedules 4 and 5.

Acquisition-Related Items

In the first quarter of 2025, we recorded net pre-tax expense items of $79 million (or $0.04 per share), including $54 million related to the U.S. International Trade Commission’s (ITC) exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States. The expenses related to the ITC orders were partially offset by insurance recoveries from insurance contracts associated with the acquisition of NJOY. Also included is a 2025 non-cash, pre-tax charge of $25 million related to a change in the fair value of the contingent payments associated with the acquisition of NJOY.

Asset Impairment, Exit and Implementation Costs

In the first quarter of 2025, we recorded a non-cash impairment charge of $873 million (or $0.52 per share) to the e-vapor reporting unit goodwill in our all other category.

Tobacco and Health and Certain Other Litigation Items

In the first quarter of 2025, we recorded pre-tax charges of $40 million (or $0.02 per share) for tobacco and health and certain other litigation items and related interest costs.

Amortization of Intangibles

In the first quarter of 2025, we recorded pre-tax amortization expense of definite-lived intangible assets of $37 million (or $0.02 per share).

SMOKEABLE PRODUCTS

Revenues and OCI

•Net revenues increased 2.9%, primarily driven by higher pricing, partially offset by higher promotional investments, lower shipment volume and a higher percentage of discount shipment volume relative to premium versus the prior year (volume mix change). Revenues net of excise taxes increased 5.2%.

•Reported OCI increased 8.3%, primarily driven by higher pricing, 2026 refunds of taxes and duties paid on imported cigarettes and lower tobacco and health and certain other litigation items, partially offset by higher promotional investments, lower shipment volume, volume mix change and higher manufacturing costs.

•Adjusted OCI increased 6.3%, primarily driven by higher pricing and 2026 refunds of taxes and duties paid on imported cigarettes, partially offset by higher promotional investments, lower shipment volume, volume mix change and higher manufacturing costs. Adjusted OCI margins increased by 0.7 percentage points to 65.1%.

Table 2 - Smokeable Products: Revenues and OCI ($ in millions)

First Quarter

2026 2025 Change

Net revenues $ 4,758 $ 4,622 2.9 %

Excise taxes (648) (715)

Revenues net of excise taxes $ 4,110 $ 3,907 5.2 %

Reported OCI $ 2,673 $ 2,469 8.3 %

NPM Adjustment Items (4) —

Asset impairment, exit and implementation costs 5 13

Tobacco and health and certain other litigation items 2 36

Adjusted OCI $ 2,676 $ 2,518 6.3 %

Reported OCI margins 1

65.0 % 63.2 % 1.8 pp

Adjusted OCI margins 1

65.1 % 64.4 % 0.7 pp

1 Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

•Smokeable products segment reported domestic cigarette shipment volume decreased 2.4%, primarily driven by the industry’s decline rate (impacted by continued discretionary income pressures on ANCs), partially offset by trade inventory movements and retail share gains.

•When adjusted for trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 4%.

•When adjusted for trade inventory movements, total domestic cigarette industry volume decreased by an estimated 5%.

•Reported cigar shipment volume decreased 0.2%.

Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)

First Quarter

2026 2025 Change

Cigarettes:

Marlboro

11,960 12,978 (7.8) %

Other premium

601 678 (11.4) %

Discount

1,306 548 100%+

Total domestic cigarettes 1

13,867 14,204 (2.4) %

Cigars:

Black & Mild 403 405 (0.5) %

Other 1 — 100%+

Total cigars 404 405 (0.2) %

Total domestic smokeable products 14,271 14,609 (2.3) %

Contract manufactured export cigarettes 2

610 — 100%+

1 Domestic cigarettes shipment volume includes Marlboro; Other premium brands, such as Virginia Slims and Parliament; and Discount brands, which include L&M and Basic. Domestic cigarettes volume includes units sold as well as promotional units sold for distribution in the U.S. and excludes units sold for distribution to Puerto Rico, U.S. Territories to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to our smokeable products segment.

2 Contract manufactured export cigarettes shipment volume represents contract manufactured cigarettes for third parties that market and sell tobacco products outside the U.S.

Retail Share and Brand Activity

•Marlboro retail share of the total cigarette category was 39.7%, a decrease of 1.4 share points versus the prior year and 0.1 share point sequentially. Marlboro share of the premium segment was 59.5%, an increase of 0.1 share point versus the prior year and 0.2 share points sequentially.

•The cigarette industry discount retail share was 33.3%, an increase of 2.4 share points versus the prior year and 0.5 share points sequentially, primarily due to continued discretionary income pressures on ANCs.

Table 4 - Smokeable Products: Domestic Cigarettes Retail Share (percent)

First Quarter

2026 2025 Percentage point change

Cigarettes:

Marlboro

39.7 % 41.1 % (1.4)

Other premium

2.1 2.2 (0.1)

Discount

3.6 1.7 1.9

Total cigarettes 45.4 % 45.0 % 0.4

Note: Retail share results for cigarettes are based on data from Circana, LLC (Circana) as well as MSAi. Circana maintains a blended retail service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System (STARS), as provided by MSAi. This service is not designed to capture sales through other channels, including the internet, direct mail and some tax-advantaged outlets. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

ORAL TOBACCO PRODUCTS

Revenues and OCI

•Net revenues increased 2.3%, driven by higher pricing, partially offset by lower shipment volume, higher promotional investments and a higher percentage of on! shipment volume relative to MST versus the prior year (product mix change). Revenues net of excise taxes increased 2.9%.

•Reported and adjusted OCI increased 0.5% and 0.2%, respectively, driven by higher pricing, partially offset by lower shipment volume, higher costs, higher promotional investments and product mix change. Adjusted OCI margins decreased 1.8 percentage points to 67.4%.

Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)

First Quarter

2026 2025 Change

Net revenues $ 669 $ 654 2.3 %

Excise taxes (22) (25)

Revenues net of excise taxes $ 647 $ 629 2.9 %

Reported OCI $ 435 $ 433 0.5 %

Asset impairment, exit and implementation costs 1 2

Adjusted OCI $ 436 $ 435 0.2 %

Reported OCI margins 1

67.2 % 68.8 % (1.6) pp

Adjusted OCI margins 1

67.4 % 69.2 % (1.8) pp

1 Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

•Oral tobacco products segment reported domestic shipment volume decreased 3.1%, primarily driven by retail share losses, partially offset by the industry’s growth rate and trade inventory movements. When adjusted for trade inventory movements, oral tobacco products segment shipment volume decreased by an estimated 8.5%.

•Total oral industry volume increased by an estimated 9.5% for the six months ended March 31, 2026, primarily driven by growth in oral nicotine pouches, partially offset by declines in MST volumes.

Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans in millions)

First Quarter

2026 2025 Change

Copenhagen 80.4 89.7 (10.4) %

Skoal 27.9 31.4 (11.1) %

on! 46.2 39.3 17.6 %

Other 15.4 15.0 2.7 %

Total oral tobacco products 169.9 175.4 (3.1) %

Note: Volume includes cans sold, as well as promotional units, but excludes non-domestic volume, which is currently not material to our oral tobacco products segment. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans shipped, one can of oral nicotine pouches, irrespective of the number of pouches in the can, is assumed to be equivalent to one can of MST.

Retail Share and Brand Activity

•Total U.S. oral tobacco category share for on! nicotine pouches was 7.8%, a decrease of 0.8 share points versus the prior year and an increase of 0.2 share points sequentially.

•The U.S. nicotine pouch category grew to 58.1% of the U.S. oral tobacco category, an increase of 9.1 share points versus the prior year. on!’s share of the nicotine pouch category was 13.4%, a decrease of 4.2 share points versus the prior year.

Table 7 - Oral Tobacco Products: Retail Share (percent)

First Quarter

2026 2025 Percentage point change

Copenhagen 13.7 % 16.9 % (3.2)

Skoal 5.3 6.5 (1.2)

on! 7.8 8.6 (0.8)

Other 2.2 2.5 (0.3)

Total oral tobacco products 29.0 % 34.5 % (5.5)

Note: Our oral tobacco products segment’s retail share results exclude non-domestic volume, which is currently not material to our oral tobacco products segment. Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans sold. Oral tobacco products are defined by Circana as domestic oral products, in the form of MST and oral nicotine pouch products (inclusive of tobacco-derived and synthetic oral nicotine products). New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. For example, one can of oral nicotine pouches, irrespective of the number of pouches in the can, is assumed to be equivalent to one can of MST. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

Altria’s Profile

We have a leading portfolio of nicotine products for U.S. nicotine consumers age 21+. We are Moving Beyond Smoking® by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers (ANC) and exploring new growth opportunities — beyond the U.S. and beyond nicotine (Vision). To achieve our Vision, we will pursue initiatives designed to promote the long-term welfare of our company, our stakeholders, society at large and the environment.

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with products covered by marketing granted orders from the U.S. Food and Drug Administration (FDA).

Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.

Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

Learn more about Altria at www.altria.com and follow us on X, Facebook and LinkedIn.

Basis of Presentation

We report our financial results in accordance with GAAP. Our management reviews OCI, which is defined as operating income before general corporate expenses and amortization of intangibles, to evaluate the performance of, and allocate resources to, our segments. Our management also reviews certain financial results, including OCI, OCI margins and diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under “2026 Full-Year Guidance.” Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management also reviews income tax rates on an adjusted basis. Our adjusted effective tax rate may exclude certain items from our reported effective tax rate. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating capital and other resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with, GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. We provide reconciliations of historical adjusted financial measures to corresponding GAAP measures in this release.

We use the equity method of accounting for our investments in ABI and Cronos and report our share of ABI’s and Cronos’s results using a one-quarter lag because ABI’s and Cronos’s results are not available in time for us to record them in the concurrent period. The one-quarter reporting lag for ABI and Cronos does not affect our cash flows.

Our reportable segments are (i) smokeable products, consisting of combustible cigarettes and machine-made large cigars, and (ii) oral tobacco products, consisting of MST and oral nicotine pouches. We have included results for NJOY, Horizon, Helix International and other business activities, which primarily consists of research and development expense related to certain new product platforms and technologies, in “All Other.” Comparisons are to the corresponding prior-year period unless otherwise stated.

Forward-Looking and Cautionary Statements

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Future dividend payments and share repurchases remain subject to the discretion of our Board.

Important factors that could cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2025. These factors and risks include the following:

▪our inability to anticipate and respond to changes in adult nicotine consumer preferences and purchase behavior;

▪our inability to compete effectively;

▪the growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume;

▪the impact of illicit trade in nicotine products and the sale of products designed to avoid the regulatory framework for nicotine products, each of which contribute to reductions in the consumption levels and shipment volumes of our businesses’ products;

▪our failure to develop and commercialize innovative products, including nicotine products that may reduce health risks relative to other nicotine products and appeal to adult nicotine consumers;

▪changes, including in macroeconomic and geopolitical conditions (including inflation, tariffs and the economic impacts of international armed conflicts), that result in shifts in adult nicotine consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;

▪unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans;

▪the risks associated with significant federal, state and local government actions, including FDA regulatory actions and inaction, and various private sector actions;

▪the risk that regulators, including the FDA, and courts may interpret laws, rules and regulations applicable to our operating companies’ products differently than we do;

▪increases in nicotine product-related taxes;

▪our failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, commercial relationships and investments in third parties, or realize the anticipated benefits of such transactions;

▪significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, geopolitical, climate and environmental conditions;

▪our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;

▪the risk that we may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment;

▪the risks associated with our Initiative, including risks relating to business continuity, our internal control over financial reporting and audit procedures and our ability to recognize the expected efficiencies;

▪the risk that we could decide, or be required, to recall products;

▪the various risks related to health epidemics and pandemics and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;

▪our inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;

▪the compliance risks associated with our expanded international business activities and the related complexity of U.S. and foreign laws and regulations applicable to those activities;

▪the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;

▪the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;

▪disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;

▪a downgrade or potential downgrade of our credit ratings;

▪the impact of heightened focus by investors and other stakeholders on our performance relating to corporate responsibility matters;

▪the failure of our, or our key service providers’ or key suppliers’, information systems to function as intended, or cyber-attacks or security breaches affecting us or our key service providers or key suppliers;

▪our failure, or the failure of our key service providers or key suppliers, to comply with laws related to personal data protection, privacy, artificial intelligence and information security;

▪the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all; and

▪the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected manner or timeframe or at all.

You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Source: Altria Group, Inc. Altria Client Services Altria Client Services

Mac Livingston, Vice President of Investor Relations Investor Relations Media Relations

Richard.M.Livingston@altria.com (804) 484-8222 www.altria.com/contact-us/media

Schedule 1

ALTRIA GROUP, INC.

and Subsidiaries

Consolidated Statements of Earnings

For the Quarters Ended March 31,

(dollars in millions, except per share data)

(Unaudited)

2026 2025 % Change

Net revenues $ 5,428 $ 5,259 3.2 %

Cost of sales 1

1,252 1,270

Excise taxes on products 1

670 740

Gross profit 3,506 3,249 7.9 %

Marketing, administration and research costs 474 488

Impairment of goodwill — 873

Operating companies income

3,032 1,888 60.6 %

Amortization of intangibles 23 37

General corporate expenses 53 63

Operating income

2,956 1,788 65.3 %

Interest and other debt expense, net 258 262

Net periodic benefit income, excluding service cost (3) (14)

(Income) losses from investments in equity securities 1

(158) (143)

Earnings before income taxes 2,859 1,683 69.9 %

Provision for income taxes 676 606

Net earnings $ 2,183 $ 1,077 100%+

Per share data:

Diluted earnings per share $ 1.30 $ 0.63 100%+

Weighted-average diluted shares outstanding 1,673 1,690 (1.0) %

1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 3.

Schedule 2

ALTRIA GROUP, INC.

and Subsidiaries

Selected Financial Data

For the Quarters Ended March 31,

(dollars in millions)

(Unaudited)

Net Revenues

Smokeable Products Oral Tobacco Products All Other Total

2026 $ 4,758 $ 669 $ 1 $ 5,428

2025 4,622 654 (17) 5,259

% Change 2.9 % 2.3 % 100%+ 3.2 %

Reconciliation:

For the quarter ended March 31, 2025

$ 4,622 $ 654 $ (17) $ 5,259

Operations 136 15 18 169

For the quarter ended March 31, 2026

$ 4,758 $ 669 $ 1 $ 5,428

Operating Companies Income (Loss)

Smokeable Products Oral Tobacco Products All Other Total

2026 $ 2,673 $ 435 $ (76) $ 3,032

2025 2,469 433 (1,014) 1,888

% Change 8.3 % 0.5 % 92.5 % 60.6 %

Reconciliation:

For the quarter ended March 31, 2025

$ 2,469 $ 433 $ (1,014) $ 1,888

Acquisition-related items - 2025

— — 71 71

Asset impairment, exit and implementation costs - 2025

13 2 873 888

Tobacco and health and certain other litigation items - 2025

36 — — 36

49 2 944 995

NPM Adjustment Items - 2026

4 — — 4

Asset impairment, exit and implementation costs - 2026

(5) (1) — (6)

Tobacco and health and certain other litigation items - 2026

(2) — — (2)

(3) (1) — (4)

Operations 158 1 (6) 153

For the quarter ended March 31, 2026

$ 2,673 $ 435 $ (76) $ 3,032

Schedule 3

ALTRIA GROUP, INC.

and Subsidiaries

Supplemental Financial Data

(dollars in millions)

(Unaudited)

For the Quarters Ended March 31,

2026 2025

The segment detail of excise taxes on products sold is as follows:

Smokeable products $ 648 $ 715

Oral tobacco products 22 25

$ 670 $ 740

The segment detail of charges for resolution expenses related to state settlement agreements included in cost of sales is as follows:

Smokeable products $ 668 $ 687

$ 668 $ 687

The segment detail of FDA user fees included in cost of sales is as follows:

Smokeable products $ 64 $ 62

Oral tobacco products 1 1

$ 65 $ 63

The detail of (income) losses from investments in equity securities is as follows:

ABI

$ (159) $ (125)

Cronos 1 (18)

$ (158) $ (143)

Schedule 4

ALTRIA GROUP, INC.

and Subsidiaries

Net Earnings and Diluted Earnings Per Share

For the Quarters Ended March 31,

(dollars in millions, except per share data)

(Unaudited)

Net Earnings Diluted EPS

2026 Net Earnings

$ 2,183 $ 1.30

2025 Net Earnings

$ 1,077 $ 0.63

% Change 100%+ 100%+

Reconciliation:

2025 Net Earnings

$ 1,077 $ 0.63

2025 Acquisition-related items

65 0.04

2025 Asset impairment, exit and implementation costs

884 0.52

2025 Tobacco and health and certain other litigation items

30 0.02

2025 Amortization of intangibles

31 0.02

2025 ABI-related special items

17 0.01

2025 Cronos-related special items

(18) (0.01)

2025 Income tax items

3 —

Subtotal 2025 special items

1,012 0.60

2026 NPM Adjustment Items

9 —

2026 Acquisition-related items

(2) —

2026 Asset impairment, exit and implementation costs

(5) —

2026 Tobacco and health and certain other litigation items

(2) —

2026 Amortization of intangibles

(20) (0.01)

2026 ABI-related special items

(1) —

2026 Cronos-related special items

(2) —

2026 Income tax items

(12) (0.01)

Subtotal 2026 special items

(35) (0.02)

Fewer shares outstanding — 0.01

Change in tax rate 11 0.01

Operations 118 0.07

2026 Net Earnings

$ 2,183 $ 1.30

Schedule 5

ALTRIA GROUP, INC.

and Subsidiaries

Reconciliation of GAAP and non-GAAP Measures

For the Quarters Ended March 31,

(dollars in millions, except per share data)

(Unaudited)

Earnings before Income Taxes Provision for Income Taxes Net Earnings Diluted EPS

2026 Reported

$ 2,859 $ 676 $ 2,183 $ 1.30

NPM Adjustment Items (11) (2) (9) —

Acquisition-related items 2 — 2 —

Asset impairment, exit and implementation costs 6 1 5 —

Tobacco and health and certain other litigation items

2 — 2 —

Amortization of intangibles 23 3 20 0.01

ABI-related special items 1 — 1 —

Cronos-related special items 2 — 2 —

Income tax items — (12) 12 0.01

2026 Adjusted for Special Items

$ 2,884 $ 666 $ 2,218 $ 1.32

2025 Reported

$ 1,683 $ 606 $ 1,077 $ 0.63

Acquisition-related items 79 14 65 0.04

Asset impairment, exit and implementation costs 888 4 884 0.52

Tobacco and health and certain other litigation items 40 10 30 0.02

Amortization of intangibles 37 6 31 0.02

ABI-related special items 21 4 17 0.01

Cronos-related special items (18) — (18) (0.01)

Income tax items — (3) 3 —

2025 Adjusted for Special Items

$ 2,730 $ 641 $ 2,089 $ 1.23

2026 Reported Net Earnings and Reported Diluted EPS

$ 2,183 $ 1.30

2025 Reported Net Earnings and Reported Diluted EPS

$ 1,077 $ 0.63

% Change 100%+ 100%+

2026 Adjusted Net Earnings and Adjusted Diluted EPS

$ 2,218 $ 1.32

2025 Adjusted Net Earnings and Adjusted Diluted EPS

$ 2,089 $ 1.23

% Change 6.2 % 7.3 %

Reported 1

Adjusted 2

2026 Effective Tax Rate 23.6 % 23.1 %

2025 Effective Tax Rate 36.0 % 23.5 %

Change (12.4) pp (0.4) pp

1 Reported effective tax rate is calculated as reported provision for income taxes divided by reported earnings before income taxes provided above.

2 Adjusted effective tax rate is calculated as provision for income taxes adjusted for special items divided by earnings before income taxes adjusted for special items provided above.

Schedule 6

ALTRIA GROUP, INC.

and Subsidiaries

Reconciliation of GAAP and non-GAAP Measures

For the Year Ended December 31, 2025

(dollars in millions, except per share data)

(Unaudited)

Earnings before Income Taxes Provision for Income Taxes Net Earnings

Diluted EPS

2025 Reported

$ 9,389 $ 2,442 $ 6,947 $ 4.12

NPM Adjustment Items (20) (5) (15) (0.01)

Acquisition-related items 76 10 66 0.04

Asset impairment, exit and implementation costs 2,184 263 1,921 1.14

Tobacco and health and certain other litigation items 58 14 44 0.03

Amortization of intangibles 132 22 110 0.06

ABI-related special items 95 20 75 0.04

Cronos-related special items (5) — (5) —

Income tax items — (5) 5 —

2025 Adjusted for Special Items

$ 11,909 $ 2,761 $ 9,148 $ 5.42

Schedule 7

ALTRIA GROUP, INC.

and Subsidiaries

Condensed Consolidated Balance Sheets

(dollars in millions)

(Unaudited)

March 31, 2026 December 31, 2025

Assets

Cash and cash equivalents $ 3,531 $ 4,474

Inventories 1,146 1,070

Other current assets 525 388

Property, plant and equipment, net 1,730 1,710

Goodwill and other intangible assets, net 17,660 17,663

Investments in equity securities 8,947 8,617

Other long-term assets 1,045 1,095

Total assets $ 34,584 $ 35,017

Liabilities and Stockholders’ Equity (Deficit)

Current portion of long-term debt $ 542 $ 1,569

Accrued settlement charges 2,837 2,178

Other current liabilities 5,028 5,407

Long-term debt 24,060 24,140

Deferred income taxes 3,464 3,370

Accrued pension costs 120 122

Accrued postretirement health care costs 935 939

Other long-term liabilities 759 744

Total liabilities 37,745 38,469

Total stockholders’ equity (deficit) attributable to Altria (3,211) (3,502)

Noncontrolling interest 50 50

Total liabilities and stockholders’ equity (deficit) $ 34,584 $ 35,017

Total debt $ 24,602 $ 25,709

Schedule 8

ALTRIA GROUP, INC.

and Subsidiaries

Supplemental Financial Data for Special Items

For the Quarters Ended March 31,

(dollars in millions)

(Unaudited)

Net Revenues Cost of

Sales Marketing,

administration

and research costs Impairment of goodwill Amortization of intangibles General

corporate

expenses Interest and other debt (income) expense, net (Income) losses from

investments in equity securities

2026 Special Items - (Income) Expense

NPM Adjustment Items $ — $ (4) $ — $ — $ — $ — $ (7) $ —

Acquisition-related items — — — — — 2 — —

Asset impairment, exit and implementation costs — — 6 — — — — —

Tobacco and health and certain other litigation items — — 2 — — — — —

Amortization of intangibles — — — — 23 — — —

ABI-related special items — — — — — — — 1

Cronos-related special items — — — — — — — 2

2025 Special Items - (Income) Expense

Acquisition-related items $ 34 $ 37 $ — $ — $ — $ 8 $ — $ —

Asset impairment, exit and implementation costs — — 15 873 — — — —

Tobacco and health and certain other litigation items — — 36 — — — 4 —

Amortization of intangibles — — — — 37 — — —

ABI-related special items — — — — — — — 21

Cronos-related special items — — — — — — — (18)

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

GRAPHIC

Filename: altriamosaica62a.jpg · Sequence: 7

Binary file (5837 bytes)

Download altriamosaica62a.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover Page Cover Page

Apr. 30, 2026

Entity Information [Line Items]

Document Type

8-K

Document Period End Date

Apr. 30, 2026

Entity Registrant Name

ALTRIA GROUP, INC.

Entity Incorporation, State or Country Code

Entity File Number

1-08940

Entity Tax Identification Number

13-3260245

Entity Address, Address Line One

6601 West Broad Street,

Entity Address, City or Town

Richmond,

Entity Address, State or Province

Entity Address, Postal Zip Code

23230

City Area Code

804

Local Phone Number

274-2200

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0000764180

Common Stock, $0.33 1/3 par value

Entity Information [Line Items]

Title of 12(b) Security

Common Stock, $0.33 1/3 par value

Trading Symbol

Security Exchange Name

NYSE

2.200% Notes due 2027

Entity Information [Line Items]

Title of 12(b) Security

2.200% Notes due 2027

Trading Symbol

MO27

Security Exchange Name

NYSE

3.125% Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

3.125% Notes due 2031

Trading Symbol

MO31

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=mo_CommonStock0.3313ParValueMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=mo_CommonStock2.200NotesDue2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=mo_CommonStock3.125NotesDue2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: